Financial performance analysis of selected Indian pharmaceutical companies during 
COVID-19 outbreak

Bhavyasri, Maddi Yasaswini Venkata Sai; Mohapatra, Lalita Mohan

doi:10.4324/9781003313663-4

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The stock price reaction to the third event was the slowest and only became statistically significant at CAR (0; 7), whereas the other two occurrences significantly reached significance at CAR (0; 2). (Bhavyasri et al,2022) By analyzing financial parameters, the study provides insights into the risk and performance landscape of the selected Indian pharmaceutical companies. The analysis of these companies' profit margins, liquidity, and solvency ratios offers a comprehensive understanding of their financial standing in the pharmaceutical sector.…”

Section: Review Of Literaturementioning

confidence: 99%

COVID-19 Crisis: A Brunt or Blossoming on Pharmaceutical Industry an Inspection of Sun Pharma, Cipla & Divi's Labs

2024

PSEN

View full text Add to dashboard Cite

The COVID-19 pandemic has emerged as a pivotal moment for the pharmaceutical industry, catalyzing profound shifts in market dynamics and operational strategies. This research paper delves into the nuanced ramifications of the pandemic on the pharmaceutical sector, with a focused examination on three prominent entities: Sun Pharma, Cipla, and Divi's Labs. Through a comprehensive analysis, this study endeavors to elucidate whether the COVID-19 crisis has posed a formidable challenge or presented opportunities for growth within these pharmaceutical companies.The objectives of this research are threefold. Firstly, it aims to investigate the impact of the COVID-19 pandemic on the profitability of pharmaceutical companies in India. Secondly, it seeks to scrutinize the fluctuations in share prices of Sun Pharma, Cipla, and Divi's Labs before and after the onset of the pandemic. Lastly, it endeavors to discern the relationship between key financial metrics such as revenue, profit, return on investment (ROI), and the corresponding share price performance of these companies.Employing a combination of quantitative methodologies and qualitative insights, this study offers valuable perspectives on the resilience and adaptability of the pharmaceutical industry in the face of unprecedented global challenges. By unraveling the intricate interplay between pandemic-induced disruptions and market dynamics, this research contributes to a deeper understanding of the evolving landscape of the pharmaceutical sector amidst the COVID-19 crisis.

show abstract

Section: Review Of Literaturementioning

confidence: 99%

COVID-19 Crisis: A Brunt or Blossoming on Pharmaceutical Industry an Inspection of Sun Pharma, Cipla & Divi's Labs

2024

PSEN

View full text Add to dashboard Cite

show abstract

Financial performance analysis of selected Indian pharmaceutical companies during COVID-19 outbreak

Cited by 1 publication

References 0 publications

COVID-19 Crisis: A Brunt or Blossoming on Pharmaceutical Industry an Inspection of Sun Pharma, Cipla & Divi's Labs

COVID-19 Crisis: A Brunt or Blossoming on Pharmaceutical Industry an Inspection of Sun Pharma, Cipla & Divi's Labs

Contact Info

Product

Resources

About